ClinicalTrials.gg
RecruitingNCT06483711Updated Nov 19, 2026

Reducing Barriers to Lifestyle Modification for Newly Diagnosed MASLD

An interventional study of Lifestyle Kit in Metabolic Dysfunction-associated Steatotic Liver Disease, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Stanford University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 19, 2026Now RecruitingFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
10 Years to 17 Years
Sex
All
01

Study summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of liver disease in the world. It is estimated that 38% of American children with obesity have steatotic liver disease. Patients of Hispanic ethnicity are disproportionately at risk of developing MASLD. This study intends to provide insight to barriers of recommended care for pediatric patients with Hispanic ethnicity and a new diagnosis of MASLD. The investigators propose to augment existing structural barriers related to health literacy, food accessibility and dietary knowledge, and access to safe physical activity through a healthy lifestyle toolkit and individualized nutritional counseling.

Read the detailed description

The Hispanic population represents the largest and fastest growing ethnic group in the United States. Patients of Hispanic ethnicity are disproportionately at risk of developing MASLD. An adult meta-analysis found a prevalence rate of 22.9% among individuals of Hispanic ethnicity. A pediatric retrospective study found that children who are Hispanic are 5 times more likely to have MASLD than their age/gender matched peers who identify as black. The etiology of why individuals of Hispanic ethnicity are at higher risk of developing MASLD, and subsequently associated co-morbidities such as insulin resistance, diabetes, and cardiovascular disease, is thought to be multifactorial. There is evidence to suggest that individuals of Hispanic ethnicity have a genetic predisposition for hepatic fat infiltration.11 Additionally, it has been postulated that social determinants of health, such as economic stability and health care access and quality contribute to an increased risk.

The American Association for the Study of Liver Diseases (AASLD) recommends lifestyle modification as the foundation of treatment for MASLD. Implementing dietary changes and increasing physical activity contribute to weight loss, which has been found to reduce hepatic steatosis. A 7-10% weight loss can improve histopathological features of MASLD, including fibrosis.Application of dietary modification, such as adherence to the Mediterranean dietary pattern, can decrease hepatic fat content, even in the absence of weight loss.Though lifestyle intervention has been found to be effective, barriers to implementation exist. In a study of adult patients of Hispanic ethnicity with a diagnosis of MASLD, access to nutritious food and a safe exercising environment limited the ability to follow through with recommended lifestyle changes.A survey study of pediatric patients with MASLD found that many lacked the opportunity for physical activity, though the majority expressed an interest in participation.16 Health literacy, or the ability to obtain and comprehend medical information, has also been found to be a barrier to effective care. In a qualitative interview study of adults with MASLD, health literacy was hindered by the availability of liver disease resources in the patient's preferred language. There is limited pediatric data regarding perceived barriers to implementing lifestyle changes. With this study, the investigators hope to minimize some of the social determinants of health that can impact Hispanic pediatric MASLD patients and help them participate in the recommended standard of care.

02

Conditions studied

  • Metabolic Dysfunction-associated Steatotic Liver Disease
03

In context

Lead sponsor

Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.

Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric and adolescent patients age 10-17 years of Hispanic ethnicity and newly diagnosed MASLD (as confirmed by ultrasound or + cardiometabolic risk factor) in the pediatric hepatology or GI clinic. Patients will also be restricted to patients who live in Alameda, Contra Costa, Solano, San Francisco, San Mateo, and Santa Clara counties due to the limitations of Fresh Approach locations. Families that include one family member who speaks English.

Exclusion criteria

Exclusion Criteria:

  • Age less than 10 and age greater than 17. Patient who do not live in Alameda, Contra Costa, Solano, San Francisco, San Mateo, and Santa Clara counties due to limitations of Fresh Approach locations. Families with no English Speakers or families whose primary language is not English or Spanish.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Healthy Lifestyle Kit Group

    Participants will receive a healthy lifestyle kit and be asked interview questions about its efficacy.

    Other: Lifestyle Kit

Interventions

  • OtherLifestyle Kit

    The investigators will provide a kit to families that contains educational information, exercise equipment, and nutritional products.

06

What researchers measure

Primary outcomes

  1. Number of Social Determinants of Health Impacting Participants

    Social Determinants of Health Screener will identify the presence of food, housing, and/or transportation insecurity.

    Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.

Secondary outcomes

  1. Mean Change from Baseline AST at 3 or 6 month follow-up appointment

    AST lab value

    Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.

  2. Mean Change from Baseline ALT at 3 or 6 month follow-up appointment

    ALT Lab value

    Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.

  3. Mean Change from Baseline GGT at 3 or 6 month follow-up appointment

    GGT Lab value

    Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.

  4. Mean BMI Change from Baseline at 3 or 6 month follow-up appointment

    BMI

    Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.

  5. Mean Weight Change from Baseline at 3 or 6 month follow-up appointment

    weight

    Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.

  6. Socioeconomic status of Participants participating in the study

    Socioeconomic status

    Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.

  7. Ethnic background of Participants participating in the study

    ethnic background

    Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.

  8. Primary language of Participants participating in the study

    primary language

    Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.

07

Study locations

1 of 1 sites recruiting
  • LPCH Stanford Weight Clinic
    Palo Alto, California 94306, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — There currently are no plans to share IPD.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Jul 2028, 27 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Jul 2025 → Apr 2026, primary completion Jul 2026 → Jul 2028 and completion Jul 2027 → Jul 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2024
First posted
Jul 3, 2024
StartActual
Apr 22, 2026was Jul 2025
Primary completionEst.
Jul 30, 2028was Jul 2026
CompletionEst.
Jul 30, 2029was Jul 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
1 site added — first site in United States
Show site
  • LPCH Stanford Weight Clinic · Palo Alto, United States
Nov 19, 2026
Start date
Jul 1, 2025→Apr 22, 2026 (actual)
Nov 19, 2026
Primary completion
Jul 30, 2026→Jul 30, 2028
Nov 19, 2026
Study completion
Jul 30, 2027→Jul 30, 2029
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • LPCH Stanford Weight Clinic · Palo Alto, United States
    Start date Jul 1, 2025→Apr 22, 2026 (now actual)
    Primary completion Jul 30, 2026→Jul 30, 2028
    Study completion Jul 30, 2027→Jul 30, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06483711
Responsible party
Rachel Herdes (CLINICAL ASSISTANT PROFESSOR, PEDIATRICS - GASTROENTEROLOGY, Stanford University) — Principal investigator
First posted
Jul 3, 2024
Start date
Apr 22, 2026
Primary completion
Jul 30, 2028 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Rachel Herdes, DO
Contact
rherdes@stanford.edu
650-497-8911
Amrita Narang, MD
Contact
anarang@stanford.edu
650-497-8911
Rachel Herdes, DO
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion